Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in adults with hypercholesterolemia
NCT07477704Phase 2Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2026
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alirocumab in hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Started Jun 2026; status: active, not recruiting.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT07477704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07477704.